Simon Nannini

Strasbourg, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.

In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: May 21, 2026

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

Journal: Clinical genitourinary cancer

Published: March 11, 2026

Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.

Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.

Journal: JCO precision oncology

Published: January 21, 2026

Cardiovascular toxicities of major oral targeted therapies used in solid tumor

Cardiovascular toxicities of major oral targeted therapies used in solid tumor

Journal: Bulletin du cancer

Published: September 30, 2025

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

Journal: ESMO open

Published: July 16, 2025

Evolution of bispecific and multispecific antibodies in cancer therapy.

Evolution of bispecific and multispecific antibodies in cancer therapy.

Journal: The Lancet regional health. Europe

Published: May 26, 2025

Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade.

Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade.

Journal: International journal of cancer

Published: March 05, 2025

Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decade.

Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decade.

Journal: International journal of cancer

Published: March 05, 2025

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 29, 2025

Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.

Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.

Journal: Cancer medicine

Published: October 24, 2024

Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature.

Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature.

Journal: Cancers

Published: July 30, 2024

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.

Journal: Current oncology (Toronto, Ont.)

Published: February 11, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026